| Field | Specification |
|---|---|
| Target | |
| Alternative names | Mitotic checkpoint serine/threonine-protein kinase BUB1 beta; MAD3/BUB1-related protein kinase; Hbubr1; Mitotic checkpoint kinase MAD3L; Protein SSK1; BUB1B; BUBR1; MAD3L; SSK1 |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human BubR1/BUB1B recombinant protein (Position: K26-E448). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone 8B3 is a mouse monoclonal antibody that recognizes mitotic checkpoint serine/threonine-protein kinase BUB1 beta (gene BUB1B) in human and rat samples and is validated for Western blot, IHC and flow cytometry. The predicted molecular weight is 119.5 kDa, and the supplier reports an observed band at about 130 kDa.
BubR1 (BUB1B) is a kinase-family protein of the spindle assembly checkpoint. As part of the mitotic checkpoint complex with MAD2, BUB3 and CDC20, it holds the anaphase-promoting complex (APC/C) inactive until every chromosome is correctly attached to the spindle, and it also helps recruit the motor CENPE to kinetochores. It is studied in mitosis, chromosome instability, aneuploidy and aging.
| Target | Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (gene BUB1B; UniProt O60566, human) |
|---|---|
| Clone | 8B3 |
| Host / Clonality / Isotype | Mouse / Monoclonal / Mouse IgG2b |
| Reactivity | Human, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3 |
| Calculated MW | 119.5 kDa |
| Observed MW | 130 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL (Human, Rat) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): human HeLa cells, human HEK293 cells, human K562 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human rectal cancer tissue, rat intestine tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with a confirmed signal (flow cytometry): HeLa cells.
Immunogen
Recombinant human BubR1/BUB1B fragment (Lys26–Glu448), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human and rat. UniProt places mitotic checkpoint serine/threonine-protein kinase BUB1 beta in the cytoplasm, nucleus and chromosome. Tissue expression noted by UniProt (human): Highly expressed in thymus followed by spleen. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
